126 related articles for article (PubMed ID: 27515688)
1. The Potential Benefits of HPV Vaccination in Previously Infected Women.
Schiller JT
EBioMedicine; 2016 Aug; 10():5-6. PubMed ID: 27515688
[No Abstract] [Full Text] [Related]
2. HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?
Vorsters A; Van Damme P; Bosch FX
Int J Infect Dis; 2019 Nov; 88():110-112. PubMed ID: 31521851
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
4. A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects.
Scherer EM; Smith RA; Gallego DF; Carter JJ; Wipf GC; Hoyos M; Stern M; Thurston T; Trinklein ND; Wald A; Galloway DA
EBioMedicine; 2016 Aug; 10():55-64. PubMed ID: 27423190
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
Godi A; Kemp TJ; Pinto LA; Beddows S
J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
[TBL] [Abstract][Full Text] [Related]
6. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.
Mollers M; Vossen JM; Scherpenisse M; van der Klis FR; Meijer CJ; de Melker HE
J Med Virol; 2013 Aug; 85(8):1379-85. PubMed ID: 23722396
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R
Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163
[TBL] [Abstract][Full Text] [Related]
8. [Vaccination against HPV in adults].
Gil Á
Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
[No Abstract] [Full Text] [Related]
9. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
[TBL] [Abstract][Full Text] [Related]
10. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
Bonanni P; Boccalini S; Bechini A
Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of antibody response to HPV vaccination in HIV infected girls].
Ołdakowska A; Marczyńska M; Dobosz S; Stańska-Perka A; Popielska J; Szczepańska-Putz M
Przegl Epidemiol; 2012; 66(4):651-5. PubMed ID: 23484395
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
14. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
15. HPV vaccination in Italy: perspectives after 1-year experience.
Icardi G
J Prev Med Hyg; 2008 Dec; 49(4):125-8. PubMed ID: 19350958
[No Abstract] [Full Text] [Related]
16. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
Nie J; Liu Y; Huang W; Wang Y
Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
[TBL] [Abstract][Full Text] [Related]
17. Prevention of cervical cancer: where immunology meets diagnostics.
Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
[TBL] [Abstract][Full Text] [Related]
18. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
20. HPV Vaccination in Males: Another Step Forward.
Cai T
EBioMedicine; 2015 Oct; 2(10):1300-1. PubMed ID: 26629518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
